摘要
目的观察培美曲塞联合顺铂治疗老年中晚期非小细胞肺癌的临床疗效及不良反应。方法选取38例住院治疗的老年中晚期非小细胞肺癌患者,采用培美曲塞联合顺铂方案化疗。其中培美曲塞500 mg/m2静脉滴注第1天;顺铂25 mg/m2静脉滴注第1,2,3天;每21 d重复,2个周期后评价1次疗效。结果治疗后有效率(RR)为34.21%,临床获益率为73.68%,其中完全缓解(CR)0例,部分缓解(PR)13例,稳定(SD)15例,进展(PD)10例;治疗后有21例患者的体力状况评分提高;毒性反应主要为Ⅰ～Ⅱ度的骨髓抑制和脱发。结论培美曲塞联合顺铂方案治疗老年中晚期非小细胞肺癌,尤其是肺腺癌,疗效好、耐受性好、不良反应轻。
Objective To evaluate the clinical effects and adverse reactions of pemetrexed （PEM） combined with cisplatin（PDD） for treating elderly advanced non-samll cell lung cancer（NSCLC）. Methods Thirty-eight elderly inpatients with NSCLC were given the chemotherapy regimen. PEM 500 mg/m2 by intravenous drip on 1 d, PDD 25 mg/m2 by intravenous drip on 1, 2, 3 d, repeated once per 21 d. The efficacy evaluation was performed once after 2 treatment cycles. Results After treatment, RR was 34.21% and the clinical benefit was 73.68%. Among them, CR was 0, PR in 13 cases, SD in 15 cases and PD in 10 cases. After treatment, the Karnofsky performance scores （KPS） in 21 cases were increased. The main toxic reactions were myelosuppression（ I - II°） and hair loss. Conclusion The regimen of PEM and PDD is well tolerable and better effective with mild adverse reactions in treating elderly NSCLC, especially lung adenocarcinoma.
出处
《中国药业》
CAS
2012年第17期79-80,共2页
China Pharmaceuticals
关键词
非小细胞肺癌
培美曲塞
顺铂
non - small cell lung
pemetrexed
cisplatin
